Day: January 8, 2023

CALGARY, Alberta, Jan. 08, 2023 (GLOBE NEWSWIRE) — Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) is providing an update on its Downstream operations following recent extreme winter storms and severe cold temperatures at the company’s U.S. and Canadian refining operations, coupled with unplanned operational challenges and third-party pipeline outages, which impacted refinery throughput and operational availability. Cenovus’s priority remains the safety of its people and the reliability and integrity of its operations. The Lloydminster Refinery has continued to run well through December and into January. However, the company’s refineries in the U.S. and the Lloydminster Upgrader experienced various degrees of unplanned operational issues, weather-related impacts and third-party pipeline outages. As a result, downstream throughput was...

Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p

Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in 69 heavily-pretreated, RANO-evaluable patients Median duration of 8.4 months on therapy as of September 28, 2022, with 77% of patients remaining on treatment Additional data to be presented at a medical meeting in the second quarter of 2023 New Drug Application submission planned for first half of 2023SOUTH SAN FRANCISCO, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced positive topline results from the ongoing, open-label, pivotal Phase 2 FIREFLY-1 trial evaluating the investigational agent, tovorafenib (DAY101), as a monotherapy in recurrent...

–   On track to fulfill all elements of Vision 3×3 to build a sustainable, profitable, leading biopharma company COPENHAGEN, Denmark, Jan. 08, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on its Vision 3×3 strategic roadmap and planned 2023 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 9, at the 41st Annual J.P. Morgan Healthcare Conference. “As we approach anticipated launch of our second endocrinology rare disease product, TransCon PTH for hypoparathyroidism, we remain on track to achieve Vision 3×3 to become a sustainable, profitable leading biopharma company,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “We are deeply committed to advancing our pipeline of endocrinology rare disease,...

ALISO VIEJO, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) — (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2022. Preliminary Unaudited ResultsPreliminary unaudited fourth quarter 2022 revenue is expected to be approximately $16.1 million, representing growth of approximately 91% compared to the prior year period, driven by:The sale of 57 Light Delivery Devices (LDD™s), expanding the installed base to 400 LDDs as of December 31, 2022; and The sale of 9,123 Light Adjustable Lenses (LAL®s).Preliminary unaudited 2022 fiscal year revenue is expected to be approximately $49.0 million, representing growth of approximately...

MARLBOROUGH, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022. Akoya reported the following preliminary financial results for the fourth quarter and full year 2022, which remain subject to quarter end closing adjustments:Revenue for the fourth quarter of 2022 is expected to be between $20.7 million and $21.2 million, as compared to $16.2 million for the corresponding quarter of last year For the fiscal year of 2022, revenue is expected to be between $74.3 million and $74.8 million, as compared to $54.9 million for fiscal year 2021“The fourth quarter of 2022 was another record quarter for Akoya, demonstrating our continued business momentum and commercial...

                                        Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc – Transaction expands Chiesi’s rare disease medicine portfolio – All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on certain Filsuvez® milestones being achieved – Total Transaction value of up to US$1.48 Billion with upfront consideration representing a 107% premium to Amryt ADS’ closing price on January 6, 2023 – Transaction unanimously approved and recommended by the Boards of both Chiesi and Amryt – Transaction supported by voting agreements from leading Amryt shareholders and directors – Transaction expected to close in the first half of 2023 Parma Italy, Boston MA and Dublin, Ireland, January 8, 2023 Chiesi Farmaceutici S.p.A. (“Chiesi”),...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR :  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced several developments in its infectious disease and oncology portfolios. These include:DARPin Radioligand Therapy platform progressing well. Disclosure of the tumor-associated protein Delta-like ligand 3 (DLL3) as the first target. Expression of DLL3 is low in healthy tissue but significantly increased in certain tumor types, providing an opportunity for selective targeting. Year-end 2022 unaudited cash and short-term deposits ~CHF249m. Company continues to maintain expected cash runway into 2026.* Molecular Partners and Novartis...

VANCOUVER, Wash. and NEW YORK, Jan. 08, 2023 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Absci management is scheduled to present on Tuesday, January 10th at 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time). This presentation time has been updated from a previous announcement and reflects the current schedule. Interested parties may access a live and archived webcast of the presentation on the company’s investor relations website at: investors.absci.com. About Absci Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™...

Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC); enrollment into forth dose level is ongoing Anticipates clinical program updates from pivotal NAVAL-1 study in EBV+ relapsed/refractory (R/R) lymphoma and Phase 1b/2 trial in EBV+ R/M NPC and other advanced EBV+ solid tumors over 2023 Cash, cash equivalents, and investments of over $90 million at year-end 2022 provide anticipated runway into late 2024 SAN DIEGO, Jan. 08, 2023 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced new clinical data from the Phase 1b/2 trial of Nana-val in patients with EBV+ R/M NPC...